Urinary proteomic profiling reveals diagnostic biomarkers and regulatory networks in myasthenia gravis
This pilot urinary proteomic study provides preliminary evidence for urinary TPD52 as a potential noninvasive biomarker for MG and suggests its possible involvement in MG pathogenesis. These findings offer new insights into the molecular mechanisms of MG and lay a foundation for applying urinary proteomics in neuroimmune disorders.
Authors
- Shi-ge San
- Xi Yang
- Jing Yang
- Kun Meng
- Fan Ye
- Chun-hua Wang
- Liang Shen
- Lianchen Xiao
- Zhen-kun Zhu
Institutions
- Hubei University of Arts and Science (CN)
- Xiangyang Central Hospital (CN)
- The Fourth People's Hospital of Ningxia Hui Autonomous Region (CN)
Publication Details
- Journal
- BMC Neurology
- Published
- 2026-01-09
- DOI
- https://doi.org/10.1186/s12883-025-04623-5
- Primary Topic
- Myasthenia Gravis and Thymoma
- Type
- article
- Field-Weighted Citation Impact
- 0.00